BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McElhinny CJ Jr, Lewin AH, Mascarella SW, Runyon S, Brieaddy L, Carroll FI. Hydrolytic instability of the important orexin 1 receptor antagonist SB-334867: possible confounding effects on in vivo and in vitro studies. Bioorg Med Chem Lett 2012;22:6661-4. [PMID: 23031594 DOI: 10.1016/j.bmcl.2012.08.109] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Kumar S, Behl T, Sehgal A, Singh S, Sharma N, Bhatia S, Al-Harassi A, Abdel-Daim MM, Bungau S. Exploring the Role of Orexinergic Neurons in Parkinson's Disease. Neurotox Res 2021. [PMID: 34495449 DOI: 10.1007/s12640-021-00411-4] [Reference Citation Analysis]
2 Caldirola D, Alciati A, Cuniberti F, Perna G. Experimental Drugs for Panic Disorder: An Updated Systematic Review. J Exp Pharmacol 2021;13:441-59. [PMID: 33889031 DOI: 10.2147/JEP.S261403] [Reference Citation Analysis]
3 Préville C, Bonaventure P, Koudriakova T, Lord B, Nepomuceno D, Rizzolio M, Mani N, Coe KJ, Ndifor A, Dugovic C, Dvorak CA, Coate H, Pippel DJ, Fitzgerald A, Allison B, Lovenberg TW, Carruthers NI, Shireman BT. Substituted Azabicyclo[2.2.1]heptanes as Selective Orexin-1 Antagonists: Discovery of JNJ-54717793. ACS Med Chem Lett 2020;11:2002-9. [PMID: 33062185 DOI: 10.1021/acsmedchemlett.0c00085] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Fuertes M, Masdeu C, Martin-Encinas E, Selas A, Rubiales G, Palacios F, Alonso C. Synthetic Strategies, Reactivity and Applications of 1,5-Naphthyridines. Molecules 2020;25:E3252. [PMID: 32708796 DOI: 10.3390/molecules25143252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zarrabian S, Riahi E, Karimi S, Razavi Y, Haghparast A. The potential role of the orexin reward system in future treatments for opioid drug abuse. Brain Research 2020;1731:146028. [DOI: 10.1016/j.brainres.2018.11.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
6 García-Brito S, Aldavert-Vera L, Huguet G, Kádár E, Segura-Torres P. Orexin-1 receptor blockade differentially affects spatial and visual discrimination memory facilitation by intracranial self-stimulation. Neurobiol Learn Mem 2020;169:107188. [PMID: 32061874 DOI: 10.1016/j.nlm.2020.107188] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Alijanpour S, Khakpai F, Ebrahimi-ghiri M, Zarrindast M. Co-administration of the low dose of orexin and nitrergic antagonists induces an antidepressant-like effect in mice. Biomedicine & Pharmacotherapy 2019;109:589-94. [DOI: 10.1016/j.biopha.2018.10.033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
8 Glamočlija U, Padhye S, Špirtović-Halilović S, Osmanović A, Veljović E, Roca S, Novaković I, Mandić B, Turel I, Kljun J, Trifunović S, Kahrović E, Kraljević Pavelić S, Harej A, Klobučar M, Završnik D. Synthesis, Biological Evaluation and Docking Studies of Benzoxazoles Derived from Thymoquinone. Molecules 2018;23:E3297. [PMID: 30545123 DOI: 10.3390/molecules23123297] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
9 Bernstein DL, Badve PS, Barson JR, Bass CE, España RA. Hypocretin receptor 1 knockdown in the ventral tegmental area attenuates mesolimbic dopamine signaling and reduces motivation for cocaine. Addict Biol 2018;23:1032-45. [PMID: 28971565 DOI: 10.1111/adb.12553] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
10 Perrey DA, Zhang Y. Therapeutics development for addiction: Orexin-1 receptor antagonists. Brain Res 2020;1731:145922. [PMID: 30148984 DOI: 10.1016/j.brainres.2018.08.025] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
11 Perrey DA, Decker AM, Zhang Y. Synthesis and Evaluation of Orexin-1 Receptor Antagonists with Improved Solubility and CNS Permeability. ACS Chem Neurosci 2018;9:587-602. [PMID: 29129052 DOI: 10.1021/acschemneuro.7b00402] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
12 Steiner N, Rossetti C, Sakurai T, Yanagisawa M, de Lecea L, Magistretti PJ, Halfon O, Boutrel B. Hypocretin/orexin deficiency decreases cocaine abuse liability. Neuropharmacology 2018;133:395-403. [PMID: 29454841 DOI: 10.1016/j.neuropharm.2018.02.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
13 Shaw JK, Ferris MJ, Locke JL, Brodnik ZD, Jones SR, España RA. Hypocretin/orexin knock-out mice display disrupted behavioral and dopamine responses to cocaine. Addict Biol 2017;22:1695-705. [PMID: 27480648 DOI: 10.1111/adb.12432] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
14 Hooshmandi M, Hosseinmardi N, Janahmadi M, Khakpai F, Rohampour K, Doostmohammadi J. Antagonism of orexin type-1 receptors (OX1Rs) attenuates naloxone-precipitated morphine withdrawal syndrome in rat dorsal hippocampus. Pharmacology Biochemistry and Behavior 2017;158:39-48. [DOI: 10.1016/j.pbb.2017.06.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
15 Levy KA, Brodnik ZD, Shaw JK, Perrey DA, Zhang Y, España RA. Hypocretin receptor 1 blockade produces bimodal modulation of cocaine-associated mesolimbic dopamine signaling. Psychopharmacology (Berl) 2017;234:2761-76. [PMID: 28667509 DOI: 10.1007/s00213-017-4673-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
16 Cramer J, Schiebel J, Wulsdorf T, Grohe K, Najbauer EE, Ehrmann FR, Radeva N, Zitzer N, Linne U, Linser R, Heine A, Klebe G. A False-Positive Screening Hit in Fragment-Based Lead Discovery: Watch out for the Red Herring. Angew Chem Int Ed Engl 2017;56:1908-13. [PMID: 28097765 DOI: 10.1002/anie.201609824] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
17 Stump CA, Cooke AJ, Bruno J, Cabalu TD, Gotter AL, Harell CM, Kuduk SD, Mcdonald TP, O’brien J, Renger JJ, Williams PD, Winrow CJ, Coleman PJ. Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology. Bioorganic & Medicinal Chemistry Letters 2016;26:5809-14. [DOI: 10.1016/j.bmcl.2016.10.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
18 Walker LC, Ch’ng SS, Lawrence AJ. Role of Lateral Hypothalamic Orexin (Hypocretin) Neurons in Alcohol Use and Abuse: Recent Advances. Curr Pharmacol Rep 2016;2:241-52. [DOI: 10.1007/s40495-016-0069-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
19 Carrive P. Orexin, Stress and Central Cardiovascular Control. A Link with Hypertension? Neurosci Biobehav Rev 2017;74:376-92. [PMID: 27477446 DOI: 10.1016/j.neubiorev.2016.06.044] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
20 Olney JJ, Navarro M, Thiele TE. Binge-like consumption of ethanol and other salient reinforcers is blocked by orexin-1 receptor inhibition and leads to a reduction of hypothalamic orexin immunoreactivity. Alcohol Clin Exp Res 2015;39:21-9. [PMID: 25623402 DOI: 10.1111/acer.12591] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
21 Keserű GM, Erlanson DA, Ferenczy GG, Hann MM, Murray CW, Pickett SD. Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia. J Med Chem 2016;59:8189-206. [DOI: 10.1021/acs.jmedchem.6b00197] [Cited by in Crossref: 120] [Cited by in F6Publishing: 97] [Article Influence: 20.0] [Reference Citation Analysis]
22 Kumar A, Chanana P, Choudhary S. Emerging role of orexin antagonists in insomnia therapeutics: An update on SORAs and DORAs. Pharmacological Reports 2016;68:231-42. [DOI: 10.1016/j.pharep.2015.09.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
23 Moorman DE, James MH, Kilroy EA, Aston-Jones G. Orexin/hypocretin neuron activation is correlated with alcohol seeking and preference in a topographically specific manner. Eur J Neurosci 2016;43:710-20. [PMID: 26750264 DOI: 10.1111/ejn.13170] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 7.3] [Reference Citation Analysis]
24 Lopez MF, Moorman DE, Aston-Jones G, Becker HC. The highly selective orexin/hypocretin 1 receptor antagonist GSK1059865 potently reduces ethanol drinking in ethanol dependent mice. Brain Res 2016;1636:74-80. [PMID: 26851547 DOI: 10.1016/j.brainres.2016.01.049] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
25 Kukkonen JP. OX2 orexin/hypocretin receptor signal transduction in recombinant Chinese hamster ovary cells. Cell Signal 2016;28:51-60. [PMID: 26582739 DOI: 10.1016/j.cellsig.2015.11.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
26 Mohammad-pour Kargar H, Azizi H, Mirnajafi-zadeh J, Ali Reza M, Semnanian S. Microinjection of orexin-A into the rat locus coeruleus nucleus induces analgesia via cannabinoid type-1 receptors. Brain Research 2015;1624:424-32. [DOI: 10.1016/j.brainres.2015.07.050] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
27 Roecker AJ, Cox CD, Coleman PJ. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. J Med Chem 2016;59:504-30. [PMID: 26317591 DOI: 10.1021/acs.jmedchem.5b00832] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 8.9] [Reference Citation Analysis]
28 Johnson PL, Federici LM, Fitz SD, Renger JJ, Shireman B, Winrow CJ, Bonaventure P, Shekhar A. OREXIN 1 AND 2 RECEPTOR INVOLVEMENT IN CO2 -INDUCED PANIC-ASSOCIATED BEHAVIOR AND AUTONOMIC RESPONSES. Depress Anxiety 2015;32:671-83. [PMID: 26332431 DOI: 10.1002/da.22403] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 6.4] [Reference Citation Analysis]
29 Brodnik ZD, Bernstein DL, Prince CD, España RA. Hypocretin receptor 1 blockade preferentially reduces high effort responding for cocaine without promoting sleep. Behav Brain Res 2015;291:377-84. [PMID: 26049058 DOI: 10.1016/j.bbr.2015.05.051] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
30 Khoo SY, Brown RM. Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA? CNS Drugs 2014;28:713-30. [PMID: 24942635 DOI: 10.1007/s40263-014-0179-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
31 Bonaventure P, Yun S, Johnson PL, Shekhar A, Fitz SD, Shireman BT, Lebold TP, Nepomuceno D, Lord B, Wennerholm M, Shelton J, Carruthers N, Lovenberg T, Dugovic C. A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects. J Pharmacol Exp Ther 2015;352:590-601. [PMID: 25583879 DOI: 10.1124/jpet.114.220392] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 8.6] [Reference Citation Analysis]
32 Beig MI, Dampney BW, Carrive P. Both Ox1r and Ox2r orexin receptors contribute to the cardiovascular and locomotor components of the novelty stress response in the rat. Neuropharmacology 2015;89:146-56. [PMID: 25239810 DOI: 10.1016/j.neuropharm.2014.09.012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
33 Winrow CJ, Renger JJ. Discovery and development of orexin receptor antagonists as therapeutics for insomnia. Br J Pharmacol 2014;171:283-93. [PMID: 23731216 DOI: 10.1111/bph.12261] [Cited by in Crossref: 86] [Cited by in F6Publishing: 88] [Article Influence: 10.8] [Reference Citation Analysis]
34 Mousavi Y, Azizi H, Mirnajafi-zadeh J, Javan M, Semnanian S. Blockade of orexin type-1 receptors in locus coeruleus nucleus attenuates the development of morphine dependency in rats. Neuroscience Letters 2014;578:90-4. [DOI: 10.1016/j.neulet.2014.06.038] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
35 Duncan MJ, Franklin KM, Peng X, Yun C, Legan SJ. Circadian rhythm disruption by a novel running wheel: roles of exercise and arousal in blockade of the luteinizing hormone surge. Physiol Behav 2014;131:7-16. [PMID: 24727338 DOI: 10.1016/j.physbeh.2014.04.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
36 Merlo Pich E, Melotto S. Orexin 1 receptor antagonists in compulsive behavior and anxiety: possible therapeutic use. Front Neurosci 2014;8:26. [PMID: 24592206 DOI: 10.3389/fnins.2014.00026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
37 Belema M, Nguyen VN, Romine JL, St. Laurent DR, Lopez OD, Goodrich JT, Nower PT, O’boyle DR, Lemm JA, Fridell RA, Gao M, Fang H, Krause RG, Wang Y, Oliver AJ, Good AC, Knipe JO, Meanwell NA, Snyder LB. Hepatitis C Virus NS5A Replication Complex Inhibitors. Part 6: Discovery of a Novel and Highly Potent Biarylimidazole Chemotype with Inhibitory Activity Toward Genotypes 1a and 1b Replicons. J Med Chem 2014;57:1995-2012. [DOI: 10.1021/jm4016203] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
38 Roecker AJ, Mercer SP, Schreier JD, Cox CD, Fraley ME, Steen JT, Lemaire W, Bruno JG, Harrell CM, Garson SL, Gotter AL, Fox SV, Stevens J, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Stellabott J, Hartman GD, Young SD, Winrow CJ, Renger JJ, Coleman PJ. Discovery of 5''-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3''-terpyridine-3'-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. ChemMedChem 2014;9:311-22. [PMID: 24376006 DOI: 10.1002/cmdc.201300447] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
39 Perrey DA, German NA, Gilmour BP, Li JX, Harris DL, Thomas BF, Zhang Y. Substituted tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor. J Med Chem 2013;56:6901-16. [PMID: 23941044 DOI: 10.1021/jm400720h] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
40 Lebold TP, Bonaventure P, Shireman BT. Selective orexin receptor antagonists. Bioorg Med Chem Lett 2013;23:4761-9. [PMID: 23891187 DOI: 10.1016/j.bmcl.2013.06.057] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 5.9] [Reference Citation Analysis]
41 Davis BJ, Erlanson DA. Learning from our mistakes: the 'unknown knowns' in fragment screening. Bioorg Med Chem Lett 2013;23:2844-52. [PMID: 23562240 DOI: 10.1016/j.bmcl.2013.03.028] [Cited by in Crossref: 116] [Cited by in F6Publishing: 94] [Article Influence: 12.9] [Reference Citation Analysis]